Skip to Content

FDA’s agenda in limbo as Biden’s nominee stalls in Senate


AP Health Writer

WASHINGTON (AP) — President Joe Biden’s pick to lead the powerful Food and Drug Administration has stalled in the narrowly divided Senate. It’s an unexpected setback that could delay long-awaited decisions on everything from electronic cigarettes to prescription opioids. Biden nominated Dr. Robert Califf for the job in November after months of vetting candidates. Califf was viewed as a safe choice because he’d previously headed the FDA under President Barack Obama and had cleared the Senate by an overwhelming vote. But Califf’s latest bid has been embroiled in disparate political controversies that threaten to sink his nomination and leave the FDA in limbo for months.

Article Topic Follows: AP National Business

Jump to comments ↓

Associated Press


KVIA ABC 7 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.

Skip to content